7 completed, 1 active not recruiting, 1 terminated. 6 Phase 1, 2 Phase 2, 1 Phase 3.
By phase and status
Follow DNL151: new trials by email Literature Review of DNL151 trials Research Report on DNL151
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
BIIB122 225 mg, BIIB122-Matching Placebo - Parkinson Disease | Phase 2 | Active not recruiting | Denali Therapeutics Inc. | 50 | 2024-10-24 | 2026-05-27 |
A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
BIIB122, Rabeprazole - Healthy Volunteer | Phase 1 | Completed | Biogen | 18 | 2024-02-12 | 2024-07-19 |
A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale
BIIB122, BIIB122-Matching Placebo - Parkinson Disease | Phase 3 | Terminated | Biogen | 7 | 2022-08-26 | 2024-06-26 |
A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80
BIIB122, BIIB122-Matching Placebo - Parkinson Disease | Phase 2 | Completed | Biogen | 650 | 2022-04-19 | 2026-06-04 |
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
BIIB122 - Healthy Volunteer | Phase 1 | Completed | Biogen | 84 | 2022-02-17 | 2023-04-18 |
A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects
[14C] BIIB122 ([14C] DNL151) - Healthy Volunteers | Phase 1 | Completed | Biogen | 7 | 2021-08-27 | 2021-12-07 |
A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects
BIIB122 (DNL151), [14C] BIIB122 ([14C] DNL151) - Healthy Volunteers | Phase 1 | Completed | Biogen | 8 | 2021-07-28 | 2021-11-17 |
Study to Evaluate DNL151 in Subjects With Parkinson's Disease
DNL151, Placebo - Parkinson's Disease | Phase 1 | Completed | Biogen | 36 | 2019-07-23 | 2023-04-18 |
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL151 in Healthy Volunteers
DNL151, Placebo - Healthy Volunteers | Phase 1 | Completed | Denali Therapeutics Inc. | 186 | 2017-11-16 | 2022-03-07 |
Conditions studied
Parkinson Disease (4) · Movement Disorders (2)
Sponsors
Biogen (7) · Denali Therapeutics Inc. (2)
Countries
United States (8) · Germany (3) · Netherlands (3) · Spain (3) · United Kingdom (3) · France (2) · Israel (2) · Italy (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · Japan (1) · Poland (1)
Top investigators
Andres Cruz-Herranz (1) · Danna Jennings, MD (1)
Results publications
PMID 40680102
NIH funding
2017 (1), 2023 (1)